Title(s):
Associate Professor of Oncology
Appointment Phone:
410-955-8964
Primary Location:
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Expertise:
Bone Marrow Transplant, General Internal Medicine, Graft-versus-Host Disease, Hematologic Malignancies
Education and Experience
Training
- University Hospital Centre of Zagreb (11000Zagreb )/ (1990)
Residencies
- Univ Of Arizona College Of Medicine (Tucson AZ)/ Internal Medicine (1997)
Fellowships
- The Johns Hopkins Hospital (Baltimore MD)/ Medical Oncology (2001)
- University of California - (San Diego CA)/ ResearchFellow/Molecular Biology (1994)
Locations
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
401 N. Broadway
Harry and Jeanette Weinberg Building
Baltimore, MD 21231
Phone: 410-502-7732
Appointment Phone: 410-955-8964
Fax: 410-614-1005
Location Map
Department / Division
- Oncology
Centers/Institutes
Centers / Institutes
- Hematologic Malignancies and Immunology and Immunotherapy Research Program
- Sidney Kimmel Comprehensive Cancer Center
Bio
Biography
1990-1991 House Officer, University of Zagreb School of Medicine, Zagreb, Croatia
Expertise
- Bone Marrow Transplant
- General Internal Medicine
- Graft-versus-Host Disease
- Hematologic Malignancies
Professional Highlights
Certification:
State of Maryland:
1997 License to Practice Medicine (D0052747)
American Board of Internal Medicine:
1997 Diplomate, Internal Medicine
2001 Diplomate, Hematology
2002 Diplomate, Medical Oncology
Previous position:
2001 - 2008: Assistant Professor of Oncology, The Johns Hopkins University School of Medicine
State of Maryland:
1997 License to Practice Medicine (D0052747)
American Board of Internal Medicine:
1997 Diplomate, Internal Medicine
2001 Diplomate, Hematology
2002 Diplomate, Medical Oncology
Previous position:
2001 - 2008: Assistant Professor of Oncology, The Johns Hopkins University School of Medicine
Research
Research and Publications
Research Summary
Dr. Luznik''s primary research interest is in the area of allogeneic blood and marrow stem cell transplantation (alloBMT). In the laboratory, there are two main areas of ongoing research. The first area focuses on understanding the mechanisms of antitumor immunity after alloBMT. The strategy is to induce immune response against antigens expressed on the tumor (tumor-specific antigens) but not on the normal host hematopoietic and epithelial tissue.
A second area of interest focuses on understanding the critical cellular and molecular mechanisms of acute and chronic GVHD. The long-term goal of these studies is to translate them into the clinic to achieve better antitumor efficacy of alloBMT and to extend the application of this procedure to patients with non-hematopoietic disorders by early induction of tolerance and better prevention of acute and chronic GVHD.
Dr. Luznik''s clinical interests are focused on the translation of the concepts developed in the laboratory to early phase clinical trials. He currently leads the multi-institutional clinical trial using high-dose cyclophosphamide as single-agent short course GVHD prophylaxis. (Principal Investigator: L. Luznik; ClinicalTrials.gov Identifier: NCT 00809276). As a part of this clinical trial, his laboratoty is also conducting a systematic study of the correlates of T-cell immune recovery with the goal of identifying critical mechanisms behind the unique ability of high-dose cyclophosphamide to prevent acute and chronic GVHD.
Journal Citations
Durakovic, N.; Bezak, K.B.; Skarica, M.; Radojcic, V.; Fuchs, E.J.; Murphy, G.F.; Luznik, L. Host-derived Langerhans cells persist after MHC-matched allografting independent of donor T cells and critically influence the alloresponses mediated by donor lymphocyte infusions. J Immunol. 2006 Oct 1;177(7):4414-4425.
Huff, C.A.; Fuchs, E.J.; Smith, B.D.; Blackford, A.; Garrett-Mayer, E.; Brodsky, R.A.; Flinn, I.W.; Ambinder, R.F.; Borrello, I.M.; Matsui, W.H.; Vogelsang, G.B.; Griffin, C.A.; Luznik, L.; Jones, R.J. Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biol Blood Marrow Transplant. 2006 Apr;12(4):414-421.
Luznik, L. Finding the best way to train the immune system against lymphoma. Leuk Lymphoma. 2006 Apr;47(4):577-579.
Bolanos-Meade, J.; Garrett-Mayer, E.; Luznik, L.; Anders, V.; Webb, J.; Fuchs, E.J.; Huff, C.A.; Matsui, W.; Borrello, I.M.; Brodsky, R.; Kasamon, Y.L.; Swinnen, L.J.; Flinn, I.W.; Ambinder, R.F.; Jones, R.J.; Hess, A.D.; Vogelsang, G.B. Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma. Biol Blood Marrow Transplant. 2007 Oct;13(10):1185-1191.
Durakovic, N.; Radojcic, V.; Powell, J.; Luznik, L. Rapamycin promotes emergence of IL-10-secreting donor lymphocyte infusion-derived T cells without compromising their graft-versus-leukemia reactivity. Transplantation. 2007 Mar 15;83(5):631-640.
Durakovic, N.; Radojcic, V.; Skarica, M.; Bezak, K.B.; Powell, J.D.; Fuchs, E.J.; Luznik, L. Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse. Blood. 2007 May 15;109(10):4564-4574.
Brodsky, R.A.; Luznik, L.; Bolanos-Meade, J.; Leffell, M.S.; Jones, R.J.; Fuchs, E.J. Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases. Bone Marrow Transplant. 2008 Oct;42(8):523-527.
Luznik, L.; O'Donnell, P.V.; Symons, H.J.; Chen, A.R.; Leffell, M.S.; Zahurak, M.; Gooley, T.A.; Piantadosi, S.; Kaup, M.; Ambinder, R.F.; Huff, C.A.; Matsui, W.; Bolanos-Meade, J.; Borrello, I.; Powell, J.D.; Harrington, E.; Warnock, S.; Flowers, M.; Brodsky, R.A.; Sandmaier, B.M.; Storb, R.F.; Jones, R.J.; Fuchs, E.J. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008 Jun;14(6):641-650.
Symons, H.J.; Levy, M.Y.; Wang, J.; Zhou, X.; Zhou, G.; Cohen, S.E.; Luznik, L.; Levitsky, H.I.; Fuchs, E.J. The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cells. Biol Blood Marrow Transplant. 2008 May;14(5):499-509.
Warlick, E.D.; O'Donnell, P.V.; Borowitz, M.; Grupka, N.; Decloe, L.; Garrett-Mayer, E.; Borrello, I.; Brodsky, R.; Fuchs, E.; Huff, C.A.; Luznik, L.; Matsui, W.; Ambinder, R.; Jones, R.J.; Douglas Smith, B. Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes. Leuk Res. 2008 Sep;32(9):1439-1447.
Bolanos-Meade, J.; Luznik, L.; Muth, M.; Matsui, W.H.; Huff, C.A.; Smith, B.D.; Levy, M.Y.; Kasamon, Y.L.; Swinnen, L.J.; Powell, J.D.; Brodsky, R.A.; Ambinder, R.F.; Jones, R.J.; Fuchs, E.J. Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen. Bone Marrow Transplant. 2009 Mar;43(6):477-480.
Fuchs, E.J.; Luznik, L.; Bolanos-Meade, J.; Miller, C.B.; Brodsky, R.A.; Ambinder, R.F.; Jones, R.J. Successful pregnancy and childbirth after reduced-intensity conditioning and partially HLA-mismatched BMT. Bone Marrow Transplant. 2009 Jun;43(12):969-970.
Kasamon, Y.L.; Luznik, L.; Leffell, M.S.; Kowalski, J.; Tsai, H.L.; Bolanos-Meade, J.; Morris, L.E.; Crilley, P.A.; O'Donnell, P.V.; Rossiter, N.; Huff, C.A.; Brodsky, R.A.; Matsui, W.H.; Swinnen, L.J.; Borrello, I.; Powell, J.D.; Ambinder, R.F.; Jones, R.J.; Fuchs, E.J. Nonmyeloablative HLA-Haploidentical BMT with High-Dose Posttransplantation Cyclophosphamide: Effect of HLA Disparity on Outcome. Biol Blood Marrow Transplant. 2009 Nov 16.
Bolanos-Meade, J.; Smith, B.D.; Gore, S.D.; McDevitt, M.A.; Luznik, L.; Fuchs, E.J.; Jones, R.J. 5-Azacytidine as Salvage Treatment in Relapsed Myeloid Tumors after Allogeneic Bone Marrow Transplantation. Biol Blood Marrow Transplant. 2010 Oct 15;In Press.
Brodsky, R.A.; Chen, A.R.; Dorr, D.; Fuchs, E.J.; Huff, C.A.; Luznik, L.; Smith, B.D.; Matsui, W.H.; Goodman, S.N.; Ambinder, R.F.; Jones, R.J. High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood. 2010 Mar 18;115(11):2136-2141.
Dezern, A.E.; Luznik, L.; Fuchs, E.J.; Jones, R.J.; Brodsky, R.A. Post-transplantation cyclophosphamide for GVHD prophylaxis in severe aplastic anemia. Bone Marrow Transplant. 2010 Sep 13.
Kanakry, C.G.; Hess, A.D.; Gocke, C.D.; Thoburn, C.; Kos, F.; Meyer, C.; Briel, J.; Luznik, L.; Smith, B.D.; Levitsky, H.; Karp, J.E. Early lymphocyte recovery following intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells. Blood. 2010 Dec 16.
Kasamon, Y.L.; Jones, R.J.; Brodsky, R.A.; Fuchs, E.J.; Matsui, W.; Luznik, L.; Powell, J.D.; Blackford, A.L.; Goodrich, A.; Gocke, C.D.; Abrams, R.A.; Ambinder, R.F.; Flinn, I.W. Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma. Ann Oncol. 2010 Jun;21(6):1203-1210.
Kasamon, Y.L.; Luznik, L.; Leffell, M.S.; Kowalski, J.; Tsai, H.L.; Bolanos-Meade, J.; Morris, L.E.; Crilley, P.A.; O'Donnell, P.V.; Rossiter, N.; Huff, C.A.; Brodsky, R.A.; Matsui, W.H.; Swinnen, L.J.; Borrello, I.; Powell, J.D.; Ambinder, R.F.; Jones, R.J.; Fuchs, E.J. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant. 2010 Apr;16(4):482-489.
Luznik, L.; Bolanos-Meade, J.; Zahurak, M.; Chen, A.R.; Smith, B.D.; Brodsky, R.; Huff, C.A.; Borrello, I.; Matsui, W.; Powell, J.D.; Kasamon, Y.; Goodman, S.N.; Hess, A.; Levitsky, H.I.; Ambinder, R.F.; Jones, R.J.; Fuchs, E.J. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010 Apr 22;115(16):3224-3230.
Luznik, L.; Fuchs, E.J. High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol Res. 2010 Jul;47(1-3):65-77.
Luznik, L.; Jones, R.J.; Fuchs, E.J. High-dose cyclophosphamide for graft-versus-host disease prevention. Curr Opin Hematol. 2010 Nov;17(6):493-499.
Radojcic, V.; Bezak, K.B.; Skarica, M.; Pletneva, M.A.; Yoshimura, K.; Schulick, R.D.; Luznik, L. Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination. Cancer Immunol Immunother. 2010 Jan;59(1):137-148.
Radojcic, V.; Pletneva, M.A.; Yen, H.R.; Ivcevic, S.; Panoskaltsis-Mortari, A.; Gilliam, A.C.; Drake, C.G.; Blazar, B.R.; Luznik, L. STAT3 signaling in CD4+ T cells is critical for the pathogenesis of chronic sclerodermatous graft-versus-host disease in a murine model. J Immunol. 2010 Jan 15;184(2):764-774.
Luznik L, Bolanos-Meade J, Zahurak M, Chen AR, Smith, BD, Brodsky R, Huff C, Borrello I, Matsui W, Powell JD, Kasamon Y, Goodman SN, Hess A, Levitsky HI, Ambinder RF, Jones RJ, Fuchs EJ. High-dose cyclophosphamide as single-agent, short-course prohylaxis of graft-versus host disease. Blood. 2010; 115(16):3224-3230.
Luznik, L and Fuchs E.J.: High dose post-transplantation cyclophosphamide to promote graft host tolerance after allogeneic hematopoietic stem cell transplantation. Immunological Research. 2010.47 (1-3);65-77.
Radojcic, V., Bezak, K.B., Skarica, M., Pletneva, M.A., Yoshimura, K., Schulick, R.D. and Luznik, L. Cyclophosphamide Enhances Antitumor Immunity by Influencing the Intratumor Regulatory and Effectors T cell Balance and Dendritic Cells Homeostasis. Cancer Immunol Immunother. 2010; 59(1):137-148.
Radojcic V, Pletneva MA, Yen HR, Ivcevic S, Panoskaltsis-Mortari A, Gilliam AC, Drake CG, Blazar BR, Luznik L. STAT3 Signaling in CD4+ T Cells Is Critical for the Pathogenesis of Chronic Sclerodermatous Graft-Versus-Host Disease in a Murine Model. Journal of Immunology. 2010; 184(2): 764-777.
Luznik, L., O'Donnell, P.V., Symons, H.J., Chen, A.R., Leffell, M.S., Zahurak, M., Piantadosi, S., Gooley, T.A., Kaup, M., Ambinder, R.F., Huff, C.A., Matsui, W.H., Bolaos-Meade, J., Borrello, I., Powell, J.D., Flowers, M.,Brodsky, R.A., Sandmaier, B.M., Storb, R.F., Jones, R.J. and E. J. Fuchs: HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, post-transplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641-650.
Durakovic, N., Radojcic, V., Powell, J.D. and Luznik, L.: Timing of Rapamycin Administration Influences Donor Lymphocyte Infusion (DLI)-mediated Graft-Versus-Host or Graft-Versus-Leukemia Reactivity. Transplantation; 2007; 83(5):631-40.
Durakovic, N., Skarica, M., Radojcic, V. Bezak, K., Powell, J., Fuchs, E., Luznik, L.: Factors Governing the Activation of Adoptively Transferred Donor T cells Infused After Allogeneic Bone Marrow Transplantation in the Mouse. Blood. 2007; 109(10):4564-4574.
Durakovic N, Bezak KB, Skarica M, Radojcic V, Fuchs EJ, Murphy GF, Luznik L.: Host-Derived Langerhans Cells Persist After MHC-matched Allografting Independent of Donor T cells and Critically Influence the Alloresponses Mediated by Donor Lymphocyte Infusions. Journal of Immunology. 2006; 177(7):4414-25.
Dr. Luznik''s primary research interest is in the area of allogeneic blood and marrow stem cell transplantation (alloBMT). In the laboratory, there are two main areas of ongoing research. The first area focuses on understanding the mechanisms of antitumor immunity after alloBMT. The strategy is to induce immune response against antigens expressed on the tumor (tumor-specific antigens) but not on the normal host hematopoietic and epithelial tissue.
A second area of interest focuses on understanding the critical cellular and molecular mechanisms of acute and chronic GVHD. The long-term goal of these studies is to translate them into the clinic to achieve better antitumor efficacy of alloBMT and to extend the application of this procedure to patients with non-hematopoietic disorders by early induction of tolerance and better prevention of acute and chronic GVHD.
Dr. Luznik''s clinical interests are focused on the translation of the concepts developed in the laboratory to early phase clinical trials. He currently leads the multi-institutional clinical trial using high-dose cyclophosphamide as single-agent short course GVHD prophylaxis. (Principal Investigator: L. Luznik; ClinicalTrials.gov Identifier: NCT 00809276). As a part of this clinical trial, his laboratoty is also conducting a systematic study of the correlates of T-cell immune recovery with the goal of identifying critical mechanisms behind the unique ability of high-dose cyclophosphamide to prevent acute and chronic GVHD.
Journal Citations
Durakovic, N.; Bezak, K.B.; Skarica, M.; Radojcic, V.; Fuchs, E.J.; Murphy, G.F.; Luznik, L. Host-derived Langerhans cells persist after MHC-matched allografting independent of donor T cells and critically influence the alloresponses mediated by donor lymphocyte infusions. J Immunol. 2006 Oct 1;177(7):4414-4425.
Huff, C.A.; Fuchs, E.J.; Smith, B.D.; Blackford, A.; Garrett-Mayer, E.; Brodsky, R.A.; Flinn, I.W.; Ambinder, R.F.; Borrello, I.M.; Matsui, W.H.; Vogelsang, G.B.; Griffin, C.A.; Luznik, L.; Jones, R.J. Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biol Blood Marrow Transplant. 2006 Apr;12(4):414-421.
Luznik, L. Finding the best way to train the immune system against lymphoma. Leuk Lymphoma. 2006 Apr;47(4):577-579.
Bolanos-Meade, J.; Garrett-Mayer, E.; Luznik, L.; Anders, V.; Webb, J.; Fuchs, E.J.; Huff, C.A.; Matsui, W.; Borrello, I.M.; Brodsky, R.; Kasamon, Y.L.; Swinnen, L.J.; Flinn, I.W.; Ambinder, R.F.; Jones, R.J.; Hess, A.D.; Vogelsang, G.B. Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma. Biol Blood Marrow Transplant. 2007 Oct;13(10):1185-1191.
Durakovic, N.; Radojcic, V.; Powell, J.; Luznik, L. Rapamycin promotes emergence of IL-10-secreting donor lymphocyte infusion-derived T cells without compromising their graft-versus-leukemia reactivity. Transplantation. 2007 Mar 15;83(5):631-640.
Durakovic, N.; Radojcic, V.; Skarica, M.; Bezak, K.B.; Powell, J.D.; Fuchs, E.J.; Luznik, L. Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse. Blood. 2007 May 15;109(10):4564-4574.
Brodsky, R.A.; Luznik, L.; Bolanos-Meade, J.; Leffell, M.S.; Jones, R.J.; Fuchs, E.J. Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases. Bone Marrow Transplant. 2008 Oct;42(8):523-527.
Luznik, L.; O'Donnell, P.V.; Symons, H.J.; Chen, A.R.; Leffell, M.S.; Zahurak, M.; Gooley, T.A.; Piantadosi, S.; Kaup, M.; Ambinder, R.F.; Huff, C.A.; Matsui, W.; Bolanos-Meade, J.; Borrello, I.; Powell, J.D.; Harrington, E.; Warnock, S.; Flowers, M.; Brodsky, R.A.; Sandmaier, B.M.; Storb, R.F.; Jones, R.J.; Fuchs, E.J. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008 Jun;14(6):641-650.
Symons, H.J.; Levy, M.Y.; Wang, J.; Zhou, X.; Zhou, G.; Cohen, S.E.; Luznik, L.; Levitsky, H.I.; Fuchs, E.J. The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cells. Biol Blood Marrow Transplant. 2008 May;14(5):499-509.
Warlick, E.D.; O'Donnell, P.V.; Borowitz, M.; Grupka, N.; Decloe, L.; Garrett-Mayer, E.; Borrello, I.; Brodsky, R.; Fuchs, E.; Huff, C.A.; Luznik, L.; Matsui, W.; Ambinder, R.; Jones, R.J.; Douglas Smith, B. Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes. Leuk Res. 2008 Sep;32(9):1439-1447.
Bolanos-Meade, J.; Luznik, L.; Muth, M.; Matsui, W.H.; Huff, C.A.; Smith, B.D.; Levy, M.Y.; Kasamon, Y.L.; Swinnen, L.J.; Powell, J.D.; Brodsky, R.A.; Ambinder, R.F.; Jones, R.J.; Fuchs, E.J. Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen. Bone Marrow Transplant. 2009 Mar;43(6):477-480.
Fuchs, E.J.; Luznik, L.; Bolanos-Meade, J.; Miller, C.B.; Brodsky, R.A.; Ambinder, R.F.; Jones, R.J. Successful pregnancy and childbirth after reduced-intensity conditioning and partially HLA-mismatched BMT. Bone Marrow Transplant. 2009 Jun;43(12):969-970.
Kasamon, Y.L.; Luznik, L.; Leffell, M.S.; Kowalski, J.; Tsai, H.L.; Bolanos-Meade, J.; Morris, L.E.; Crilley, P.A.; O'Donnell, P.V.; Rossiter, N.; Huff, C.A.; Brodsky, R.A.; Matsui, W.H.; Swinnen, L.J.; Borrello, I.; Powell, J.D.; Ambinder, R.F.; Jones, R.J.; Fuchs, E.J. Nonmyeloablative HLA-Haploidentical BMT with High-Dose Posttransplantation Cyclophosphamide: Effect of HLA Disparity on Outcome. Biol Blood Marrow Transplant. 2009 Nov 16.
Bolanos-Meade, J.; Smith, B.D.; Gore, S.D.; McDevitt, M.A.; Luznik, L.; Fuchs, E.J.; Jones, R.J. 5-Azacytidine as Salvage Treatment in Relapsed Myeloid Tumors after Allogeneic Bone Marrow Transplantation. Biol Blood Marrow Transplant. 2010 Oct 15;In Press.
Brodsky, R.A.; Chen, A.R.; Dorr, D.; Fuchs, E.J.; Huff, C.A.; Luznik, L.; Smith, B.D.; Matsui, W.H.; Goodman, S.N.; Ambinder, R.F.; Jones, R.J. High-dose cyclophosphamide for severe aplastic anemia: long-term follow-up. Blood. 2010 Mar 18;115(11):2136-2141.
Dezern, A.E.; Luznik, L.; Fuchs, E.J.; Jones, R.J.; Brodsky, R.A. Post-transplantation cyclophosphamide for GVHD prophylaxis in severe aplastic anemia. Bone Marrow Transplant. 2010 Sep 13.
Kanakry, C.G.; Hess, A.D.; Gocke, C.D.; Thoburn, C.; Kos, F.; Meyer, C.; Briel, J.; Luznik, L.; Smith, B.D.; Levitsky, H.; Karp, J.E. Early lymphocyte recovery following intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells. Blood. 2010 Dec 16.
Kasamon, Y.L.; Jones, R.J.; Brodsky, R.A.; Fuchs, E.J.; Matsui, W.; Luznik, L.; Powell, J.D.; Blackford, A.L.; Goodrich, A.; Gocke, C.D.; Abrams, R.A.; Ambinder, R.F.; Flinn, I.W. Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma. Ann Oncol. 2010 Jun;21(6):1203-1210.
Kasamon, Y.L.; Luznik, L.; Leffell, M.S.; Kowalski, J.; Tsai, H.L.; Bolanos-Meade, J.; Morris, L.E.; Crilley, P.A.; O'Donnell, P.V.; Rossiter, N.; Huff, C.A.; Brodsky, R.A.; Matsui, W.H.; Swinnen, L.J.; Borrello, I.; Powell, J.D.; Ambinder, R.F.; Jones, R.J.; Fuchs, E.J. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant. 2010 Apr;16(4):482-489.
Luznik, L.; Bolanos-Meade, J.; Zahurak, M.; Chen, A.R.; Smith, B.D.; Brodsky, R.; Huff, C.A.; Borrello, I.; Matsui, W.; Powell, J.D.; Kasamon, Y.; Goodman, S.N.; Hess, A.; Levitsky, H.I.; Ambinder, R.F.; Jones, R.J.; Fuchs, E.J. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010 Apr 22;115(16):3224-3230.
Luznik, L.; Fuchs, E.J. High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol Res. 2010 Jul;47(1-3):65-77.
Luznik, L.; Jones, R.J.; Fuchs, E.J. High-dose cyclophosphamide for graft-versus-host disease prevention. Curr Opin Hematol. 2010 Nov;17(6):493-499.
Radojcic, V.; Bezak, K.B.; Skarica, M.; Pletneva, M.A.; Yoshimura, K.; Schulick, R.D.; Luznik, L. Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination. Cancer Immunol Immunother. 2010 Jan;59(1):137-148.
Radojcic, V.; Pletneva, M.A.; Yen, H.R.; Ivcevic, S.; Panoskaltsis-Mortari, A.; Gilliam, A.C.; Drake, C.G.; Blazar, B.R.; Luznik, L. STAT3 signaling in CD4+ T cells is critical for the pathogenesis of chronic sclerodermatous graft-versus-host disease in a murine model. J Immunol. 2010 Jan 15;184(2):764-774.
Luznik L, Bolanos-Meade J, Zahurak M, Chen AR, Smith, BD, Brodsky R, Huff C, Borrello I, Matsui W, Powell JD, Kasamon Y, Goodman SN, Hess A, Levitsky HI, Ambinder RF, Jones RJ, Fuchs EJ. High-dose cyclophosphamide as single-agent, short-course prohylaxis of graft-versus host disease. Blood. 2010; 115(16):3224-3230.
Luznik, L and Fuchs E.J.: High dose post-transplantation cyclophosphamide to promote graft host tolerance after allogeneic hematopoietic stem cell transplantation. Immunological Research. 2010.47 (1-3);65-77.
Radojcic, V., Bezak, K.B., Skarica, M., Pletneva, M.A., Yoshimura, K., Schulick, R.D. and Luznik, L. Cyclophosphamide Enhances Antitumor Immunity by Influencing the Intratumor Regulatory and Effectors T cell Balance and Dendritic Cells Homeostasis. Cancer Immunol Immunother. 2010; 59(1):137-148.
Radojcic V, Pletneva MA, Yen HR, Ivcevic S, Panoskaltsis-Mortari A, Gilliam AC, Drake CG, Blazar BR, Luznik L. STAT3 Signaling in CD4+ T Cells Is Critical for the Pathogenesis of Chronic Sclerodermatous Graft-Versus-Host Disease in a Murine Model. Journal of Immunology. 2010; 184(2): 764-777.
Luznik, L., O'Donnell, P.V., Symons, H.J., Chen, A.R., Leffell, M.S., Zahurak, M., Piantadosi, S., Gooley, T.A., Kaup, M., Ambinder, R.F., Huff, C.A., Matsui, W.H., Bolaos-Meade, J., Borrello, I., Powell, J.D., Flowers, M.,Brodsky, R.A., Sandmaier, B.M., Storb, R.F., Jones, R.J. and E. J. Fuchs: HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, post-transplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641-650.
Durakovic, N., Radojcic, V., Powell, J.D. and Luznik, L.: Timing of Rapamycin Administration Influences Donor Lymphocyte Infusion (DLI)-mediated Graft-Versus-Host or Graft-Versus-Leukemia Reactivity. Transplantation; 2007; 83(5):631-40.
Durakovic, N., Skarica, M., Radojcic, V. Bezak, K., Powell, J., Fuchs, E., Luznik, L.: Factors Governing the Activation of Adoptively Transferred Donor T cells Infused After Allogeneic Bone Marrow Transplantation in the Mouse. Blood. 2007; 109(10):4564-4574.
Durakovic N, Bezak KB, Skarica M, Radojcic V, Fuchs EJ, Murphy GF, Luznik L.: Host-Derived Langerhans Cells Persist After MHC-matched Allografting Independent of Donor T cells and Critically Influence the Alloresponses Mediated by Donor Lymphocyte Infusions. Journal of Immunology. 2006; 177(7):4414-25.
Research Interests
- Non-Hodgkin''s Lymphoma
- Leukemia
- Graft vs. Host Diseases
More Info
Languages
- English
Memberships
1998 present: American Society of Hematology
1998 present: American Society of Bone Marrow Transplantation
1998 present: American Society of Bone Marrow Transplantation
Clinical Trials
- single-agent, short course GVHD prophylaxis
- high-dose cyclophosphamide
- Lymphoma
- Leukemia
Additional Resources
Facebook
Twitter
Sharecare
Blogs
YouTube
RSS
Podcasts